Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11699019 | 0.94 | ADH1C (0.38) | ADH1CADH1AADH4TSHR | |
| SCHEMBL11699441 | 0.92 | ADH1C (0.41) | ADH1CADH1AADH4TSHR | |
| SCHEMBL6653799 | 0.88 | ADH1A (0.31) | ADH1CADH1A | |
| SCHEMBL26772 | 0.82 | TSHR (0.41) | ADH1CADH1AADH4TSHR | |
| Butane SCHEMBL11523278 | 0.81 | LMNA (0.44) | ADH1CADH1AADH4 | |
| SCHEMBL7209887 | 0.80 | — | — | |
| SCHEMBL2035531 | 0.79 | — | — | |
| SCHEMBL270411 | 0.78 | ADH1A (0.38) | ADH1CADH1AADH4TSHR | |
| SCHEMBL271668 | 0.78 | ADH1C (0.47) | ADH1CADH1AADH4TSHR | |
| SCHEMBL10940372 | 0.78 | TSHR (0.34) | ADH1CADH1AADH4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132449-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| US-20230416294-A1 | DECITABINE ANALOGS FOR IMMUNOLOGICAL AND ONCOLOGICAL THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2023-12-28 | — | — | US | disclosed |
| WO-2022035852-A1 | DECITABINE ANALOGS FOR IMMUNOLOGICAL AND ONCOLOGICAL THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-8552175-B2 | Sulfur transfer reagents for oligonucleotide synthesis | A.M. Chemicals, Inc. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110137021-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | A.M. Chemicals, Inc. | 2011-06-09 | — | — | US | disclosed |
| US-7847075-B2 | 2-Azapurine compounds and their use | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7723528-B2 | Sulfur transfer reagents for oligonucleotide synthesis | AM CHEMICALS LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306358-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009148719-A1 | SULFER TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1214331-B1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1097939-B1 | Method for the synthesis of isoguanosine and of its 2'-derivatives | BAYER AG (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-0778898-B1 | REDUCTION OF NONSPECIFIC HYBRIDIZATION BY USING NOVEL BASE-PAIRING SCHEMES | BAYER AG (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20010026918-A1 | Reduction of nonspecific hybridization by using novel base-pairing schemes | COLLINS MARK L (US) | 2001-10-04 | — | — | US | disclosed |
| US-6232462-B1 | SYNTHESIS OF AN ISOGUANOSINE DERIVATIVE USED AS ANTISENSE AND APTAMER THERAPEUTICS AND DRUG DISCOVERY | BAYER CORPORATION | 2001-05-15 | — | — | US | disclosed |
| EP-1097939-A2 | Method for the synthesis of isoguanosine and its 2'-derivatives | Bayer Corporation (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6140496-A | Precursors for deoxyribonucleotides containing non-standard nucleosides | BENNER, STEVEN | 2000-10-31 | — | — | US | disclosed |
| US-5780610-A | OLIGONUCLEOTIDE APTAMERS INCLUDING COMPLEMENTARY NONNATURAL NUCLEOTIDE UNITS | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 1998-07-14 | — | — | US | disclosed |
| US-5681702-A | MINIMIZES BACKGROUND NOISE | CHIRON CORPORATION (US) | 1997-10-28 | — | — | US | disclosed |
| US-4046884-A | N-(α-Aminoalkylidene)phosphor- and phosphonamidates, and method for controlling insects | VELSICOL CHEMICAL CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306358-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | POLRMT, TST, DNTT | ADH1C 3080/4885ADH1A 3543/4885ADH4 2428/4885 |
| US-20230416294-A1 | DECITABINE ANALOGS FOR IMMUNOLOGICAL AND ONCOLOGICAL THERAPY | CDA, DCTD, ADA | ADH1C 2056/4885ADH1A 816/4885ADH4 1845/4885 |
| US-20010026918-A1 | Reduction of nonspecific hybridization by using novel base-pairing schemes | UNG, SAMHD1, RNGTT | ADH1C 467/4885ADH1A 725/4885ADH4 669/4885 |
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ADAR, AMPD2, NSUN2 | ADH1C 2721/4885ADH1A 2106/4885ADH4 2081/4885 |
| US-20110137021-A1 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | TST, POLRMT, DNTT | ADH1C 2805/4885ADH1A 3622/4885ADH4 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.